HIV Viral Rebound Due to a Possible Drug–Drug Interaction between Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide and Calcium-Containing Products: Report of 2 Cases-Reference-Cited by-同舟云学术

HIV Viral Rebound Due to a Possible Drug–Drug Interaction between Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide and Calcium-Containing Products: Report of 2 Cases

Published:2019-01-01 Issue: Volume:18 Page:232595821882165
ISSN:2325-9582
Container-title:Journal of the International Association of Providers of AIDS Care (JIAPAC)
language:en
Short-container-title:J Int Assoc Provid AIDS Care

Author:

Kang-Birken S. Lena¹²^ORCID,El-sayed Dena¹,Prichard John¹

Affiliation:

1. Immunology Clinic, Ventura County Medical Center, Ventura, CA, USA

2. Thomas J. Long School of Pharmacy and Health Sciences, University of the Pacific, Stockton, CA, USA

Abstract

Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) is a potent fixed-dose, once-daily regimen for HIV-1 treatment and has rare emergence of drug resistance. We report a potential drug–drug interaction in 2 female patients both receiving treatment for HIV and cerebral toxoplasmosis: one case between E/C/F/TAF with calcium carbonate and a second case involving leucovorin as calcium salt. Both cases resulted in rise in HIV RNA levels and emergence of M184 V mutation and resistance to elvitegravir and raltegravir. To the best of our knowledge, these 2 cases are the first reports of rapid emergence of mutation from coadministration of E/C/F/TAF and calcium.

Publisher

SAGE Publications

Subject

Infectious Diseases,Dermatology,Immunology

Link

http://journals.sagepub.com/doi/pdf/10.1177/2325958218821653

Reference11 articles.

1. Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials

2. Brief Report: Randomized, Double-Blind Comparison of Tenofovir Alafenamide (TAF) vs Tenofovir Disoproxil Fumarate (TDF), Each Coformulated With Elvitegravir, Cobicistat, and Emtricitabine (E/C/F) for Initial HIV-1 Treatment: Week 144 Results

3. Analysis of early resistance development at the first failure timepoint in elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate-treated patients

4. Rare emergence of drug resistance in HIV-1 treatment-naïve patients receiving elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide for 144 weeks

5. Pharmacokinetics of Once-Daily Boosted Elvitegravir When Administered in Combination With Acid-Reducing Agents

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical Relevance of Drug Interactions in People Living with Human Immunodeficiency Virus on Antiretroviral Therapy—Update 2022: Systematic Review;Pharmaceutics;2023-10-18

2. A computational overview of integrase strand transfer inhibitors (INSTIs) against emerging and evolving drug-resistant HIV-1 integrase mutants;Archives of Microbiology;2023-03-26

3. Use of dietary supplements containing polyvalent cations and antacids among people with HIV and its impact on viral suppression;AIDS;2021-06-01

4. Interactions between antiretroviral therapy and complementary and alternative medicine: a narrative review;Clinical Microbiology and Infection;2020-09

5. Gastrointestinal drugs (Jan 2019–Dec 2019);Side Effects of Drugs Annual;2020